Multivariable analysis incorporating the total number of ctDNA mutations in 6 significant genes, clinical factors, IGH rearrangements, del(17p), and plasma DNA concentration
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . | RRMM-PI score . |
|---|---|---|---|---|---|---|
| No. of ctDNA mutations, n ≥ 2 | 1.2 | 3.5 | 2.0 | 6.0 | 9.5 × 10−6 | 3 |
| No. of ctDNA mutations, n = 1 | 0.8 | 2.2 | 1.3 | 3.7 | .0018 | 2 |
| t(11;14) (FISH) | 0.7 | 2.0 | 1.2 | 3.3 | .0049 | 2 |
| No. of prior regimens, n ≥ 3 | 1.0 | 2.8 | 1.6 | 4.8 | 3.3 × 10−4 | 2 |
| No. of prior regimens, n = 2 | 0.4 | 1.5 | 0.8 | 2.8 | .17 | 0 |
| Plasma DNA concentration: high | 0.5 | 1.7 | 1.1 | 2.6 | .019 | 1 |
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . | RRMM-PI score . |
|---|---|---|---|---|---|---|
| No. of ctDNA mutations, n ≥ 2 | 1.2 | 3.5 | 2.0 | 6.0 | 9.5 × 10−6 | 3 |
| No. of ctDNA mutations, n = 1 | 0.8 | 2.2 | 1.3 | 3.7 | .0018 | 2 |
| t(11;14) (FISH) | 0.7 | 2.0 | 1.2 | 3.3 | .0049 | 2 |
| No. of prior regimens, n ≥ 3 | 1.0 | 2.8 | 1.6 | 4.8 | 3.3 × 10−4 | 2 |
| No. of prior regimens, n = 2 | 0.4 | 1.5 | 0.8 | 2.8 | .17 | 0 |
| Plasma DNA concentration: high | 0.5 | 1.7 | 1.1 | 2.6 | .019 | 1 |
HRs for PFS evaluated by Cox PH model incorporating the total number of ctDNA mutations in the 6 prognostically significant genes and clinical factors (treatment indication and number of prior therapies), IGH rearrangements (by FISH), 17p deletion (by BMPC-seq), and plasma DNA concentration in 161 RRMM cases analyzed by both ctDNA-seq and BMPC-seq.
High and low plasma DNA concentration by a median split. Final Cox PH model after stepwise variable selection minimizing Akaike’s information criterion are shown.